Abstract PS5-04-02: Interim results: Real world study of treatment discontinuations and modifications for patients with HER2-positive metastatic breast cancer on trastuzumab deruxtecan on a Canadian patient support program
Observational study reveals treatment discontinuation rates in HER2-positive metastatic breast cancer patients, suggesting early challenges in therapy management.
Key Points
The study aims to describe real-world treatment outcomes for HER2-positive metastatic breast cancer patients receiving trastuzumab deruxtecan in Canada.
Observational study design involving patients enrolled in a Canadian patient support program.
Data collected from June 2022 to August 2023, focusing on treatment initiation and modifications.
Primary outcomes included rates of treatment discontinuation and dose modifications using descriptive summaries.
347 patients were enrolled, with a median follow-up of 5.6 months.
Cumulative probabilities of treatment discontinuation at 3, 6, and 9 months were 10.2%, 18.2%, and 29.7%, respectively.
Median time to treatment discontinuation was reported as 14.3 months overall, and 15.2 months for patients with stable brain metastases.
Cite This Study
Brezden‐Masley et al. (2026) studied this question.